Citations

Showing 10 of 108094 citations.

HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome
Natesampillai, Sekar, Cummins, Nathan W. , Nie, Zilin , Sampath, Rahul , Baker, Jason V. , Henry, Keith , Pinzone, Marilia Rita , O’Doherty, Una , Bren, Gary D., Katzmann, David J. , Badley, Andrew D. , Polley, Eric C. , Cummins, Nathan W , Badley, Andrew D , O’Doherty, Una

Mayo Clinic

Journal of Virology | April 10, 2018 | Volume: 92 | Issue: 13 | Pages: No page available

10.1128/jvi.00037-18 | PMID 29643240 Get It

ABSTRACT HIV protease is known to cause cell death, which is dependent upon cleavage of procaspase 8. HIV protease cleavage of procaspase 8 generates Casp8p41, which directly binds Bak with nanomolar affinity, causing Bak activation and consequent cell death. Casp8p41 can also bind Bcl2 with nanomolar affinity, in which case cell death is averted. Central memory CD4 T cells express high levels of Bcl2, possibly explaining why those cells do not die when they reactivate HIV. Here, we determine that the Casp8p41-Bcl2 complex is polyubiquitinated and degraded by the proteasome. Ixazomib, a proteasome inhibitor in clinical use, blocks this pathway, increasing the abundance of Casp8p41 and causing more cells to die in a Casp8p41-dependent manner. IMPORTANCE The Casp8p41 pathway of cell death is unique to HIV-infected cells yet is blocked by Bcl2. Once bound by Bcl2, Casp8p41 is polyubiquitinated and degraded by the proteasome. Proteasome inhibition blocks degradation of Casp8p41, increasing Casp8p41 levels and causing more HIV-infected cells to die.
HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia
Yan, Fei , Pang, Jiuxia, Gao, Zhe , Al‐Kali, Aref , Haynes, Christy L. , Litzow, Mark R. , Liu, Shujun , Haynes, Christy L , Liu, Shujun , Shen, Na

Mayo Clinic

ACS Applied Materials & Interfaces | April 10, 2018 | Volume: 10 | Issue: 17 | Pages: 14454-14462

10.1021/acsami.8b01696 | PMID 29668254 Get It

Fibronectin (Alpha-2-0psonic Globulin): Its Function and Applications in Trauma Surgery
Wick, Mark R.

Mayo Clinic

Military Medicine | April 10, 2018 | Volume: 148 | Issue: 5 | Pages: 456-457

10.1093/milmed/148.5.456 Get It

Arthroscopic Treatment of Iliopsoas Snapping in Patients With Radiographic Acetabular Dysplasia Using Iliopsoas Fractional Lengthening and Capsular Plication
Hartigan, David E. , Perets, Itay , Close, Mary R., Walsh, John P. , Chaharbakhshi, Edwin O., Mohr, Mitchell R., Domb, Benjamin G.

Mayo Clinic

Arthroscopy | April 10, 2018 | Volume: 34 | Issue: 6 | Pages: 1841-1850

10.1016/j.arthro.2018.01.027 | PMID 29653792 Get It

Purpose The purpose of this study was to evaluate the greater than 2‐year patient‐reported outcomes (PROs) and patient satisfaction of patients who were treated with hip arthroscopy for snapping iliopsoas tendons that were painful with concomitant acetabular dysplasia and who underwent iliopsoas lengthening for symptomatic iliopsoas tendon snapping with concomitant capsular plication and treatment of hip impingement. Secondary measures included observation of the change in the Tönnis grade at greater than 2 years' follow‐up. Methods Between July 2009 and December 2011, data on patients with a lateral center‐edge angle (LCEA) of less than 25° (range, 19°‐24°) who underwent hip arthroscopy with central‐compartment iliopsoas fractional lengthening and capsular plication were prospectively collected and retrospectively reviewed. Interportal capsular repair was performed using between 2 and 5 simple sutures. Patients also underwent procedures to treat hip impingement pathology. All patients had preoperative and minimum 2‐year postoperative PRO measures: modified Harris Hip Score, Hip Outcome Score–Activities of Daily Living subscale, Hip Outcome Score–Sports‐Specific subscale, and Non‐arthritic Hip Score. The visual analog scale score and patient satisfaction with surgery (from 0 to 10) were also collected. Radiographs were analyzed preoperatively and at latest follow‐up to assess progression of the Tönnis grade. Results We analyzed 32 patients who met the inclusion criteria (30 female and 2 male patients; mean age, 25 years). The mean LCEA and anterior center‐edge angle were 21.6° and 25.5°, respectively. Four patients required revision arthroscopy for labral retears. Among the 28 patients who did not undergo revision surgery, the modified Harris Hip Score, Hip Outcome Score–Activities of Daily Living subscale, Hip Outcome Score–Sports‐Specific subscale, and Non‐arthritic Hip Score improved from 68.7 to 83.5, from 64.9 to 86.6, from 71.6 to 86.7, and from 52.6 to 75.8, respectively ( P < .001). The visual analog scale score improved from 5.6 preoperatively to 1.9 at latest follow‐up ( P < .001). The mean patient satisfaction rating was 8.0. There was no radiographic progression of the Tönnis grade at final follow‐up. Conclusions This study showed that patients with an LCEA of less than 25° and associated painful iliopsoas snapping can be treated by addressing concomitant pathology and performing central‐compartment fractional lengthening of the iliopsoas tendon with concomitant capsular plication and have high satisfaction, improvement in PROs, and improved pain scores, without significant progression of osteoarthritis. Level of Evidence Level IV, case series.
Histopathology of granulomatous liver disease
Lewis, Jason

Mayo Clinic

Clinical Liver Disease | April 10, 2018 | Volume: 11 | Issue: 3 | Pages: 77-80

10.1002/cld.695 | PMID 30992794 Get It

Volumetric laser endomicroscopy interpretation and feature analysis in dysplastic Barrett's esophagus
Kamboj, Amrit K. , Wolfsen, Herbert C. , Trindade, Arvind J. , Ganguly, Eric K. , Otaki, Fouad , Chan, Daniel K. , Zakko, Liam , Visrodia, Kavel , Lutzke, Lori S., Wang, Kenneth K, Leggett, Cadman L. , Kahn, Allon , Trindade, Arvind J , Chan, Daniel, Lutzke, Lori, Leggett, Cadman L , Otaki, Fouad

Mayo Clinic

Journal of Gastroenterology and Hepatology | April 10, 2018 | Volume: 33 | Issue: 10 | Pages: 1761-1765

10.1111/jgh.14153 | PMID 29633412 Get It

AbstractBackground and AimVolumetric laser endomicroscopy (VLE) is used to identify Barrett's esophagus (BE) dysplasia. Selection of a dysplastic region of interest (ROI) can be challenging due to feature variability across a large amount of data. The degree of agreement among VLE users in selecting a ROI has not been studied.MethodsHigh‐definition videos that divided a VLE scan from 18 patients with biopsy‐proven BE dysplasia into 1‐cm segments were reviewed using a four‐quadrant grid superimposed for systematic interpretation. VLE scans were selected based on image quality and appropriate visualization of BE epithelium. Four experienced VLE users rated each quadrant as dysplastic or non‐dysplastic. For quadrants rated as dysplastic, reviewers selected a single timeframe with representative features. A high‐degree of agreement among reviewers was defined as ≥75% agreement on the quadrant diagnosis and ≥50% agreement on selected timeframe (±2 s).ResultsThirty‐one videos, each 32 s in length, comprising 124 quadrants were reviewed. There was high‐agreement among reviewers in 99 (80%) quadrants, of which 68 (69%) were rated as dysplastic. Compared with quadrants rated as non‐dysplastic, ROIs of quadrants rated as dysplastic contained a higher number of epithelial glands (12.7 vs 1.2, P < 0.001) with atypical architecture (54 vs 1, P < 0.001). A statistically significant difference was observed between the signal intensity profiles of quadrants rated as dysplastic and quadrants rated as non‐dysplastic (P = 0.004).ConclusionThis study highlights that experienced VLE users can identify ROIs with high‐degree of agreement. Selected ROIs contained VLE features associated with BE dysplasia.
Inhibiting focal adhesion kinase (FAK) blocks IL-4 induced VCAM-1 expression and eosinophil recruitment in vitro and in vivo
Aulakh, Gurpreet Kaur , Petri, Björn , Colarusso, Pina , Lee, James J. , Patel, Kamala D. , Wójcik, Katarzyna

Mayo Clinic

Journal of Leukocyte Biology | April 10, 2018 | Volume: 104 | Issue: 1 | Pages: 147-158

10.1002/jlb.3ma1117-429r | PMID 29633338 Get It

Abstract Leukocyte recruitment plays a critical role during both normal inflammation and chronic inflammatory diseases, and ongoing studies endeavor to better understand the complexities of this process. Focal adhesion kinase (FAK) is well known for its role in cancer, yet it also has been shown to regulate aspects of neutrophil and B16 melanoma cell recruitment by rapidly influencing endothelial cell focal adhesion dynamics and junctional opening. Recently, we found that FAK related non-kinase (FRNK), a protein that is often used as a FAK dominant negative, blocked eosinophil transmigration by preventing the transcription of vascular cell adhesion molecule-1 (VCAM-1) and eotaxin-3 (CCL26). Surprisingly, the blocking occurred even in the absence of endogenous FAK. To better understand the role of FAK in leukocyte recruitment, we used a FAK-specific inhibitor (PF-573228) and determined the effect on IL-4 induced eosinophil recruitment in vitro and in vivo. PF-573228 prevented the expression of VCAM-1 and CCL26 expression in IL-4-stimulated human endothelial cells in vitro. As a result, eosinophil adhesion and transmigration were blocked. PF-572338 also prevented IL-4-induced VCAM-1 expression in vivo. Using brightfield intravital microscopy, we found that PF-573228 decreased leukocyte rolling flux, adhesion, and emigration. We specifically examined eosinophil recruitment in vivo by using an eosinophil-GFP reporter mouse and found PF-573228 attenuated eosinophil emigration. This study reveals that a FAK inhibitor influences inflammation through its action on eosinophil recruitment. FAK inhibitor affects eosinophil recruitment in vivo using a new eosinophil reporter animal.
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Haeberlein, Samantha Budd , Carrillo, María C. , Hendrix, James A. , Kerchner, Geoff, Margolin, Richard , Maruff, Paul , Tong, Gary, Tome, Maria, Murray, Melissa E. , Nelson, Peter T. , Sano, Mary , Mattsson, Niklas , Sultzer, David L. , Montine, Thomas J. , Jack, Clifford R. , Kolb, Hartmuth C. , Petersen, Ronald C. , Vemuri, Prashanthi , Canniere, Megan Zoschg, Resnick, Susan M. , Romano, Gary, Harten, Argonde C. van , Bain, Lisa J. , Siemers, Eric , Jack, Clifford R , Vemuri, Prashanthi , Murray, Melissa E , Knopman, David S. , Miller, David S. , Schneider, Julie A. , Wolk, David A. , Maruff, Paul

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 563-575

10.1016/j.jalz.2018.03.002 | PMID 29653607 Get It

AbstractThe Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the “A, T, N System” (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.
Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA‐AA Research Framework
Khachaturian, Ara S. , Hayden, Kathleen M. , Mielke, Michelle M. , Lutz, Michael W. , Gustafson, Deborah , Kukull, Walter A. , Mohs, Richard C. , Khachaturian, Zaven S., Mielke, Michelle M , Tang, Yi

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 532-534

10.1016/j.jalz.2018.03.003 | PMID 29653605 Get It

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, Clifford R. , Bennett, David A. , Blennow, Kaj , Carrillo, María C. , Dunn, Billy , Haeberlein, Samantha Budd , Jagust, William J. , Jessen, Frank , Karlawish, Jason , Liu, Enchi , Montine, Thomas J. , Phelps, Creighton H., Rankin, Katherine P. , Scheltens, Philip , Siemers, Eric , Snyder, Heather M. , Contributors, Elliott, Cerise, Masliah, Eliezer , Ryan, Laurie, Silverberg, Nina, Bennett, David A. , Jack, Clifford R , Scheltens, Philip , Holtzman, David M. , Molinuevo, José Luís , Rowe, Christopher Cleon , Sperling, Reisa Anne , Contributors

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 535-562

10.1016/j.jalz.2018.02.018 | PMID 29653606 Get It

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a “research framework” because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six‐stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker‐based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker‐based research should not be considered a template for all research into age‐related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β‐amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.